Impact Biomedical (IBO) Non-Current Deferred Tax Liability (2022 - 2026)

Impact Biomedical (IBO) has 5 years of Non-Current Deferred Tax Liability data on file, last reported at $688000.0 in Q1 2026.

• Quarterly Non-Current Deferred Tax Liability fell 78.95% year-over-year to $688000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $688000.0 (down 78.95% YoY) and the FY2025 annual result came in at $688000.0, down 78.95% from the prior year.
• Non-Current Deferred Tax Liability was little changed at $688000.0 in Q1 2026, from $688000.0 in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $3.3 million in Q4 2024 to a low of $688000.0 in Q4 2025.
• A 5-year average of $2.9 million and a median of $3.2 million in 2022 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2024 — Non-Current Deferred Tax Liability rose 1.02% — and 2025, when it sank 78.95%.
• Tracing IBO's Non-Current Deferred Tax Liability over 5 years: stood at $3.2 million in 2022, then changed by 0.0% to $3.2 million in 2023, then rose by 1.02% to $3.3 million in 2024, then slumped by 78.95% to $688000.0 in 2025, then changed by 0.0% to $688000.0 in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $688000.0 (Q1 2026), $688000.0 (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.